Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy

Objective. To evaluate the correlation of Ki-67 as a proliferation marker to prostate-specific antigen doubling time (PSADT), Gleason score and its possible role as a predictor of PSA relapse after radical prostatectomy in early prostate cancer (PC). Material and methods. Out of 660 patients detected with PC in the Swedish branch of the European Randomized Study of Prostate Cancer, 270 were managed with active surveillance. During follow-up (mean 63 months), 70 men were treated with radical retropubic prostatectomy (RRP). In 50 of these patients the preoperative PSADT was calculated and archive prostatectomy specimens were stained for Ki-67. The quantification of positive staining cells was performed by counting five to 15 randomly selected microscopic fields using an eyepiece graticule at 400×magnification and at least 1000 tumour cells were counted for each patient. One pathologist, blinded to the PSADT values, performed the pathological assessment. The correlation between Ki-67, PSADT and Gleason grade was explored. Cox proportional hazard model was used to evaluate the prognostic power for Ki-67 and other markers on the risk of PSA relapse after RRP. Results. Ki-67 was not correlated with PSADT (p=0.45) but was correlated with Gleason grade (p<0.0001). In the Cox proportional hazard model Ki-67 (p=0.03) [hazard ratio (HR) 2.49, 95% confidence interval (CI) 1.07–5.80] and total PSA (p=0.0068) (HR 1.86, 95% 1.19–2.92) were associated significantly with the risk of disease progression. Conclusion. In men with screen-detected, clinically low-grade, low-stage prostate cancer, Ki-67 may be a valuable prognostic marker of PSA relapse after radical prostatectomy.

[1]  Lennart Franzén,et al.  How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. , 2006, The Journal of urology.

[2]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[3]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[4]  C. Abbou,et al.  EAU guidelines on prostate cancer. , 2009, European urology.

[5]  K. Ali,et al.  PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section , 2006 .

[6]  S. Nordling,et al.  Ki-67, p53, ER Receptors, Ploidy and S Phase as Long-Term Prognostic Factors in T1 Node-Negative Breast Cancer , 2006, Tumor Biology.

[7]  C. Bangma,et al.  Overdiagnosis and overtreatment of early detected prostate cancer , 2007, World Journal of Urology.

[8]  D. Neal,et al.  P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. , 1992, British journal of urology.

[9]  M. Roobol,et al.  Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 1997, The Prostate.

[10]  J W Moul,et al.  Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. , 1996, The Journal of urology.

[11]  Hans Garmo,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[12]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[13]  P. Lipponen,et al.  Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. , 1997, European urology.

[14]  V. Khoo,et al.  Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  T. Stamey,et al.  Clinical observations on the doubling time of prostate cancer. , 1993, European urology.

[16]  L. Klotz,et al.  Active surveillance versus radical treatment for favorable-risk localized prostate cancer , 2006, Current treatment options in oncology.

[17]  A. Llombart‐Bosch,et al.  Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. , 2005, European urology.

[18]  A. Bergh,et al.  Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. , 1997, The Journal of urology.

[19]  L. Denis,et al.  The European randomized study of screening for prostate cancer , 1997, Cancer.

[20]  E. Bergstralh,et al.  PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. , 2001, Mayo Clinic proceedings.

[21]  M. Roobol,et al.  The story of the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.

[22]  Hans Lilja,et al.  Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma , 2004, Cancer.

[23]  M. Hammond,et al.  Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.